一个新型的表皮模型,使用初级腺炎辅助性皮细胞
Isabel Haferland1, Andreas Pinter1, Tanja Rossmanith2
1Goethe University Frankfurt, University Hospital, Department of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany.
Journal of tissue engineering and regenerative medicine
|April 14, 2025
概括
研究人员开发了一种新的体外表皮肤模型,使用来自hidradenitis suppurativa (HS) 病变的原始细胞. 该模型通过检查生物标志物和屏障功能,有助于研究HS和测试局部治疗.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 补腺炎 (HS) 是一种慢性炎症性皮肤疾病,其特征是结节,,以及鼻腔道.
- 目前的研究重点是了解HS的发病性和开发新疗法,因为缺乏致病性治疗.
- 现有的HS细胞培养模型包括原发性皮肤细胞,血液细胞和活体扩展物.
研究的目的:
- 使用HS病变的原始细胞建立一个分层的体外表皮模型.
- 评估该模型对研究HS的实用性,包括生物标志物识别和屏障功能分析.
- 探索HS的新局部治疗选择.
主要方法:
- 从HS损伤皮肤中分离质细胞.
- 在潜水条件下的跨井系统中培养角质细胞.
- 通过将细胞提升到空气-液体界面来诱导表皮分化.
- 免疫组织化学染色以评估分化模式.
- 检测炎症性细胞因子分泌 (IL-1β,TNF-α).
主要成果:
- 建立的HS表皮模型表现出预期的分化模式.
- 该模型证明了关键炎症性细胞因子的分泌,包括互白素-1β和瘤坏死因子-α.
- 该模型为研究HS特异性生物标志物和皮肤屏障特性提供了一个平台.
结论:
- 一个分层的体外HS表皮模型使用初级病变细胞已经成功建立.
- 这个模型模仿了HS皮肤的关键方面,包括分化和炎症性细胞因子的产生.
- 该模型是推动HS研究和评估潜在局部治疗的宝贵工具.
相关概念视频
Renewal of Skin Epidermal Stem Cells
2.4K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.4K
Clinical Applications of Epidermal Stem Cells
2.6K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.6K


